Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

NCT06967480 · clinicaltrials.gov ↗

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Myasthenia Gravis
Anti-AChR Antibody Positive

Interventions

DRUG: Ravulizumab

Sponsor

Alexion Pharmaceuticals, Inc.